Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
New Scripts Summary
Ok, I managed to update all the numbers and below you can find a summary of the most important differences, mainly ATH Numbers and Market Share for V for weekly and monthly data and this is what we care for;
V WEEKLY Old Numbers Summary
TRx ATH = 26,373 on Week Ending 4/May/2018
NRx ATH = 10,395 on Week Ending 27/Apr/2018
Refills ATH = 16,438 on Week Ending 1/Dec/2017
TRx ATH Market Share = 33.05% on Week Ending 25/May/2018
NRx ATH Market Share = 32.34% on Week Ending 25/May/2018
Refills ATH Market Share = 33.92% on Week Ending 18/May/2018
V WEEKLY NEW Numbers Summary
TRx ATH = 27,476 on Week Ending 1/Dec/2017
NRx ATH = 10,796 on Week Ending 27/Apr/2018
Refills ATH = 17,260 on Week Ending 1/Dec/2017
TRx ATH Market Share = 32.72% on Week Ending 25/May/2018
NRx ATH Market Share = 32.11% on Week Ending 25/May/2018
Refills ATH Market Share = 33.41% on Week Ending 18/May/2018
V MONTHLY Old Numbers Summary
RETAIL TRx ATH = 108,980 in March-2018
INST. TRx ATH = 10,096 in Dec-2017
TOTAL RETAIL TRx ATH = 118,036 in Dec-2017
NRx ATH = 43,420 in March-2018
Refills ATH = 78,466 in Dec-2017
RETAIL TRx ATH Market Share = 32.04% in Apr-2018
INST. TRx ATH Market Share = 28.29% in Dec-2017
TOTAL RETAIL TRx ATH Market Share = 31.50% in Apr-2018
NRx ATH Market Share = 32.00% in Mar-2018
Refills ATH Market Share = 31.38% in Apr-2018
V MONTHLY NEW Numbers Summary
RETAIL TRx ATH = 112,883 in March-2018
INST. TRx ATH = 10,363 in Dec-2017
TOTAL RETAIL TRx ATH = 122,386 in Dec-2017
NRx ATH = 44,969 in March-2018
Refills ATH = 81,420 in Dec-2017
RETAIL TRx ATH Market Share = 31.74% in Apr-2018
INST. TRx ATH Market Share = 28.50% in Dec-2017
TOTAL RETAIL TRx ATH Market Share = 31.28% in Apr-2018
NRx ATH Market Share = 29.62% in Mar-2018
Refills ATH Market Share = 32.33% in Apr-2018
http://www.vascepa.com
Been a while i haven't checked the website
Nicely done with all the updates, links, comparison vs Lovaza....etc
Scripts Update for Week Ending 01/06
Changes in reporting as explained before
Short week – Memorial Day
V
TRx: 25,706 {vs 27,155; -5.34%} Sector -4.11% -- {ATH = 27,425}
NRx: 9,608 {vs 10,772; -10.81%} Sector -10.74% -- {ATH = 10,796}
Ref: 16,098 {vs 16,383; -1.74%} Sector +0.38% -- {ATH = 17,260}
GenL
TRx: 50,428 {vs 52,180; -3.36%}
NRx: 18,945 {vs 21,094; -10.19%}
L
TRx: 3,447 {vs 3,657; -5.74%}
NRx: 1,388 {vs 1,676; -17.18%}
V TRx Market Share: 32.30% vs 32.72% -- 3rd ATH --- {ATH = 32.72%}
V NRx Market Share: 32.09% vs 32.11% -- 2nd ATH --- {ATH = 32.11%}
V Ref Market Share: 32.43% vs 33.13% --- 6th ATH --- {ATH = 33.41%}
New vs Old
Excel attached from Jan-16
https://drive.google.com/file/d/1D9oz0k1cNJWTQoIDBOn5qJhs6IhgIRVA/view?usp=drivesdk
Details of Changes
link: https://drive.google.com/file/d/1oTGdp8ovXHS4_jEGEaLJLrxWsiMS7tsO/view?usp=drivesdk
SCRIPTS CHANGE
NEW CHANGES ON BLOOMBERG TERMINAL. New Long Term Care Data (LTC) has been added going back to Jan-2016 and now all numbers changed
It is going to take some time to figure the changes and report new numbers.
The changes will create a positive change as greater depth and breadth is being added
Scripts Update for Week Ending 25/05
Good Numbers – Market Share ATH in TRx & NRx – 2nd ATH in Refills
V
TRx: 26,105 {vs 25,708; +1.54%} Sector +1.06% -- 3rd ATH (ATH=26,373)
NRx: 10,332 {vs 9,984; +3.86%} Sector +0.79% -- 3rd ATH (ATH=10,395)
Ref: 15,773 {vs 15,760; +0.08%} Sector +1.24% -- 4th ATH (ATH=16,438)
GenL
TRx: 49,653 {vs 49,328; +0.66%}
NRx: 20,182 {vs 20,382; -0.98%}
L
TRx: 3,227 {vs 3,121; +3.40%}
NRx: 1,430 {vs 1,364; +4.84%}
V TRx Market Share: 33.05% vs 32.89% -- ATH
V NRx Market Share: 32.34% vs 31.39% -- ATH
V Ref Market Share: 33.53% vs 33.92% --- 2nd ATH
Scripts Update for Week Ending 18/05
V
TRx: 25,708 {vs 25,476; +0.91%} Sector -1.09% -- 4th ATH
NRx: 9,948 {vs 10,152; -2.01%} Sector -2.25% -- 8th ATH
Ref: 15,760 {vs 15,324; +2.85%} Sector -0.29% -- 5th ATH
GenL
TRx: 49,328 {vs 50,319; -1.97%}
NRx: 20,382 {vs 20,914; -2.54%}
L
TRx: 3,121 {vs 3,226; -3.25%}
NRx: 1,364 {vs 1,356; +0.59%}
V TRx Market Share: 32.89% vs 32.24% -- ATH
V NRx Market Share: 31.39% vs 31.31%
V Ref Market Share: 33.92% vs 32.88% --- ATH
No scripts update
I won’t be able to update the numbers today as I am not at the office. Monday I’ll post them
April-2018 vs. April-2017 (Retail + Inst. Data)
V
TRx: 117,610 {vs 93,522; +25.76%} -- Sector +8.08% --- 3rd ATH
NRx: 42,984 {vs 36,048; +19.24%} – Sector +10.64% -- 2nd ATH
Ref: 74,626 {vs 57,474; +29.84%} – Sector +6.67% -- 4th ATH
Gen L
TRx: 240,362 {vs 245,183; -1.97%}
NRx: 86,659 {vs 84,373; +2.71%}
L
TRx: 15,421 {vs 6,782; +127%}
NRx: 5,911 {vs 2,097; +182%}
V Apr-2018 Retail+Inst. TRx Market Share: 31.50% vs 27.07% in Apr-2017 – ATH
V Apr -2018 Retail+Inst. NRx Market Share: 31.71% vs 29.42% in Apr -2017 -- 2nd ATH
V Apr -2018 Retail+Inst. Ref Market Share: 31.38% vs 25.78% in Apr -2017 – ATH
Total Monthly Retail + Institutional Data April-2018
Institutional Numbers back on track. 2nd ATH in Inst# & Great Mkt Share across the board
V
TRx: 117,610 {vs 117,933; -0.23%} -- Sector -2.38% --- 3rd ATH
(Inst # 9,970 vs 8,953; +11.36% -- Inst Sec -1.28% -- Inst Mkt Sh 26.64% vs 23.62%) -- {Inst Number 2nd ATH & Inst Mkt Share ATH}
NRx: 42,984 {vs 43,420; -1.00%} – Sector -0.09% -- 2nd ATH
Ref: 74,626 {vs 74,513; +0.15%} – Sector -3.64% -- 4th ATH
Gen L
TRx: 240,362 {vs 248,180; -3.15%}
(Inst # 25,922 vs 27,360; -5.26%)
NRx: 86,659 {vs 85,972; +0.80%}
L
TRx: 15,421 {vs 16,380; -5.85%}
(Inst # 1,526 vs 1,590; -4.03%)
NRx: 5,911 {vs 6,287; -5.98%}
V Monthly Retail + Inst. TRx Market Share: 31.50% vs 30.83% -- ATH
V Monthly Retail + Inst. NRx Market Share: 31.71% vs 32.00% -- 2nd ATH
V Monthly Retail + Inst. Ref Market Share: 31.38% vs 30.19% -- ATH
Scripts Update for Week Ending 11/05
V
TRx: 25,476 {vs 26,373; -3.40%} Sector -3.46% -- 6th ATH
NRx: 10,152 {vs 10,353; -1.94%} Sector -2.14% -- 5th ATH
Ref: 15,324 {vs 16,020; -4.34%} Sector -4.36% -- 7th ATH
GenL
TRx: 50,319 {vs 52,066; -3.36%}
NRx: 20,914 {vs 21,340; -2.00%}
L
TRx: 3,226 {vs 3,414; -5.51%}
NRx: 1,356 {vs 1,437; -5.64%}
V TRx Market Share: 32.24% vs 32.22% -- 2nd ATH -- (ATH = 32.65%)
V NRx Market Share: 31.31% vs 31.25%
V Ref Market Share: 32.88% vs 32.88% -- 2nd ATH -- (ATH = 32.95%)
Total Monthly Retail ONLY Data April-2018
V
TRx: 107,640 {vs 108,980; -1.23%} – Sector -2.50% -- 4th ATH
NRx: 42,984 {vs 43,420; -1.00%} – Sector -0.09% -- 2nd ATH
Ref: 64,656 {vs 65,560; -1.37%} – Sector -4.06%
Gen L
TRx: 214,440 {vs 220,820; -2.89%}
NRx: 86,659 {vs 85,972; +0.80%}
L
TRx: 13,895 {vs 14,790; -6.05%}
NRx: 5,911 {vs 6,287; -5.98%}
Monthly Retail TRx Market Share: 32.04% vs 31.64% --- ATH
Monthly Retail NRx Market Share: 31.71% vs 32.00% --- 2nd ATH
Monthly Retail Refills Market Share: 32.26% vs 31.38% --- ATH
Scripts Update for Week Ending 04/05
Great Numbers – ATH in TRx & Refills; 2nd ATH in NRx
V
TRx: 26,373 {vs 25,542; +3.25%} Sector +4.62% -- ATH
NRx: 10,353 {vs 10,395; -0.40%} Sector +2.67% -- 2nd ATH
Ref: 16,020 {vs 15,147; +5.76%} Sector +5.99% -- ATH
GenL
TRx: 52,066 {vs 49,580; +5.01%}
NRx: 21,340 {vs 20,557; +3.81%}
L
TRx: 3,414 {vs 3,117; +9.53%}
NRx: 1,437 {vs 1,318; +9.03%}
V TRx Market Share: 32.23% vs 32.65% -- 2nd ATH -- (ATH = 32.65%)
V NRx Market Share: 31.25% vs 32.21%
V Ref Market Share: 32.88% vs 32.95% -- 2nd ATH -- (ATH = 32.95%)
Marz,
I guess there is kind of a mistake.
Im trying to get the full equity coverage report to check if its true
will keep you posted
Important
Anyone got the below on their platform????
There must a problem or a mistake for sure :)
"BofA/Merrill Lynch lowered its price target on Amarin Corporation (NASDAQ: AMRN) to $58.00 (from $59.00) while maintaining a Neutral rating."
Link: https://www.streetinsider.com/Analyst+PT+Change/Amarin+Corporation+%28AMRN%29+PT+Lowered+to+%2458+at+BofAMerrill+Lynch/14172311.html
Murphy,
"If the big funds sitting on the fence want in
after R.It results they will take it down
just like they did with FB from iPo $43 to $18"
You may have a valid point in there, but keep in mind that most funds have internal restrictions / structure / rules / requirements
Majority of the funds are not allowed (self internal structure) to invest in stocks below $5
Those who do, take a small exposure relative to their size.
So if funds sitting on the fence wants in, after red-it results, dropping this down won't be helpful for them, JMO
Regards,
Scripts Update for Week Ending 27/04
Good Numbers and Market Share
V
TRx: 25,542 {vs 25,144; +1.58%} Sector +0.02% -- 4th ATH
NRx: 10,395 {vs 10,192; +1.99%} Sector +1.19% -- ATH
Ref: 15,147 {vs 14,952; +1.30%} Sector -0.79%
GenL
TRx: 49,580 {vs 49,798; -0.44%}
NRx: 20,557 {vs 20,336; +1.09%}
L
TRx: 3,117 {vs 3,282; -5.03%}
NRx: 1,318 {vs 1,361; -3.16%}
V TRx Market Share: 32.65% vs 32.14% -- ATH
V NRx Market Share: 32.21% vs 31.96% -- 2nd ATH -- (ATH = 32.28%)
V Ref Market Share: 32.95% vs 32.27% -- ATH
AMARIN REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS
REDUCE-IT Study On-Track for Reporting Top-Line Results by the End of Q3 2018
Management to Host Conference Call at 7:30 a.m. ET Today
BEDMINSTER, N.J. and DUBLIN, Ireland, May 02, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the three months ended March 31, 2018, and provided an update on company operations.
Key Amarin achievements through March 31, 2018 include:
R&D progress: The REDUCE-IT cardiovascular outcomes study, designed to provide data to support a significantly expanded market opportunity for Vascepa® (icosapent ethyl), is estimated to have reached the 100% mark for onset of the 1,612 target primary major adverse cardiovascular events (MACE) specified in the study design. Amarin anticipates that MACE from the study will be adjudicated through Q2 2018, consistent with the company's objective of reporting top-line results from this important study before the end of Q3 2018.
U.S. revenue growth: Recognized $43.8 million in net product revenue from Vascepa sales in Q1 2018 compared to $34.3 million in Q1 2017, an increase of 27%.
U.S. prescription growth: Increased normalized prescriptions for Vascepa by 25% and 27% compared to Q1 2017 based on data from Symphony Health Solutions and IQVIA, respectively.
International development: Announced the first international approval for Vascepa with the regulatory approval of Vascepa in Lebanon. The clinical trial of Vascepa for approval in China is in process.
Cash balance: As of March 31, 2018, Amarin had a cash balance of $129.0 million, which includes approximately $70.0 million in net cash proceeds from the equity offering announced in February 2018, compared to $73.6 million at December 31, 2017.
"There is tremendous energy and excitement within Amarin currently as we approach the results of the REDUCE-IT study and prepare for targeted future growth," stated John F. Thero, president and chief executive officer. "The unmet medical need remains large for cost-effective therapies that lower cardiovascular risk beyond the risk reduction achieved with standard of care statin therapy alone. We are pleased that increasing numbers of physicians are prescribing Vascepa to help their patients and we are confident that the results from the REDUCE-IT study will lead to better informed decisions regarding patient care."
REDUCE-IT Cardiovascular Outcomes Study
REDUCE-IT is designed to determine if intervention with 4 grams/day of prescription pure EPA Vascepa will lower rates of major adverse cardiovascular events in statin-treated patients with persistent hypertriglyceridemia and other cardiovascular risk factors. Motivated by the vision of Amarin and its scientific collaborators in identifying a large unmet medical need in this important patient population, and facilitated by the differentiation of Vascepa from earlier generation triglyceride-lowering therapies, this is the first ever prospective study of this population with any therapy.
The primary endpoint of this global, double-blind study is the time to the first occurrence of a composite of primary major adverse cardiovascular events (MACE). Results will be compared between the Vascepa and placebo groups. The study was designed to accumulate 1,612 MACE at which level the study was robustly designed to have 90% power to detect a 15% relative risk reduction in MACE between the Vascepa and placebo arms of the study. The study is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA.
As previously reported, Amarin estimates that the onset of approximately 1,612 MACE has occurred. In March 2018, patients in the study began to complete their final clinical site visits, a key step towards study completion.
Amarin is intentionally blinded to the results of the study and will remain blinded to such results until after the study is completed and the database is locked. Final patient visits will be followed by completing data entry for the more than 35,000 patient years of study in REDUCE-IT, and typical database quality control measures, known as cleaning. In parallel, adjudication will be completed for all MACE which occurred during the study, including adjudication for certain events which, per protocol, cannot be finally adjudicated until patients complete their final site visit and results are available from certain non-invasive diagnostic testing conducted during such site visits. These steps will be followed by the database lock and final efficacy and safety analyses, including analysis of the trial's primary endpoint of first MACE events in the study, and the analyses of more than thirty pre-defined secondary and tertiary endpoints. Winding down a study of this magnitude to completion typically takes many months. The company believes that it is on track to achieve its objective of reporting top-line results from this important study before the end of Q3 2018.
Financial Update
Net product revenue for the three months ended March 31, 2018 and 2017 was $43.8 million and $34.3 million, respectively. The increase in net product revenue was primarily attributable to increases in new and recurring prescriptions of Vascepa.
During the first quarter, based on data from Symphony Health Solutions and IQVIA, Amarin experienced continued prescription growth and increase in Vascepa market share, particularly among detailed physicians. These sources reported estimated normalized total Vascepa prescriptions of approximately 381,000 and 392,000, respectively, for the three months ended March 31, 2018, representing growth of approximately 25% and 27%, respectively, over levels reported for the first three months of the prior year.
The company recognized licensing revenue of $0.1 million and $0.3 million in the three months ended March 31, 2018 and 2017, respectively, related to agreements for the commercialization of Vascepa outside the United States.
Cost of goods sold for the three months ended March 31, 2018 and 2017 was $10.6 million and $8.2 million, respectively. Gross margin on net product revenue was 76% for each of the three months ended March 31, 2018 and 2017.
Selling, general and administrative expenses in the three months ended March 31, 2018 and 2017 were $43.4 million and $34.2 million, respectively. This increase is due primarily to increased promotional activities, including commercial spend for anticipated expansion following successful REDUCE-IT results, and increased co-promotion fees, including an accrual for co-promotion tail payments as well as an increase in co-promotion fees calculated on increased gross margin resulting from higher net product revenue. The tail co-promotion fees, which are calculated as a percentage of the 2018 co-promotion fee, are payable in 2019 through 2021. Such tail co-promotion fees will be accrued throughout 2018.
Research and development expenses in the three months ended March 31, 2018 and 2017 were $11.8 million and $10.8 million, respectively. This increase in expense was primarily driven by the timing of REDUCE-IT and related costs.
Under U.S. GAAP, Amarin reported a net loss of $24.1 million in the first quarter of 2018, or basic and diluted loss per share of $0.08. This net loss included $3.8 million in non-cash stock-based compensation expense. Amarin reported a net loss of $20.9 million in the first quarter of 2017, or basic and diluted loss per share of $0.08. This net loss included $3.4 million in non-cash stock-based compensation expense.
Excluding non-cash gains or losses for stock-based compensation, non-GAAP adjusted net loss was $20.3 million for the first quarter of 2018, or non-GAAP adjusted basic and diluted loss per share of $0.07, compared to non-GAAP adjusted net loss of $17.6 million for the first quarter of 2017, or non-GAAP adjusted basic and diluted loss per share of $0.07.
Amarin reported cash and cash equivalents of $129.0 million as of March 31, 2018. Excluding proceeds from the equity financing completed in the first quarter and excluding other financing-related amounts (interest and royalty) and without the company's high level of research and development payments, most of which relates to advancing the REDUCE-IT study to completion this year, net cash outflow in the quarter ended March 31, 2018 was approximately $0.1 million. Cash outflows relating to research and development in Q1 2018 totaled approximately $11.3 million and cash paid for interest and royalties, in aggregate, was approximately $5.9 million.
As of March 31, 2018, the company had $39.2 million in net accounts receivable ($57.6 million in gross accounts receivable before allowances and reserves) and $35.1 million in inventory.
As of March 31, 2018, Amarin had approximately 293.6 million American Depository Shares (ADSs) and ordinary shares outstanding, 32.8 million common share equivalents of Series A Convertible Preferred Shares outstanding and approximately 25.7 million equivalent shares underlying stock options at a weighted-average exercise price of $3.35, as well as 12.4 million equivalent shares underlying restricted or deferred stock units.
Amarin's partner in the Middle East and North Africa, or MENA region, in the first quarter of 2018 obtained approval for Vascepa in Lebanon. Amarin anticipates additional approvals in the MENA region, including potential additional approvals in 2018. Amarin's partner for China, Eddingpharm, is progressing in its clinical study of Vascepa in China. This study, which recently commenced, potentially positions Vascepa to be the first prescription grade EPA product to receive drug approval in China.
Conference call and webcast information
Amarin will host a conference call at 7:30 a.m. ET today, May 2, 2018. The call will be webcast live with slides and accessible through the investor relations section of the company's website at www.amarincorp.com. The call can also be heard via telephone by dialing 877-407-8033. A replay of the call will be made available for a period of two weeks following the conference call. To hear a replay of the call, dial 877-481-4010 (inside the United States) or 919-882-2331 (outside the United States). A replay of the call will also be available through the company's website shortly after the call. For both dial-in numbers please use conference ID 27922.
Use of non-GAAP adjusted financial information
Included in this press release are non-GAAP adjusted financial information as defined by U.S. Securities and Exchange Commission Regulation G. The GAAP financial measure most directly comparable to each non-GAAP adjusted financial measure used or discussed, and a reconciliation of the differences between each non-GAAP adjusted financial measure and the comparable GAAP financial measure, is included in this press release after the condensed consolidated financial statements.
Non-GAAP adjusted net loss was derived by taking GAAP net loss and adjusting it for non-cash stock-based compensation expense. Management uses these non-GAAP adjusted financial measures for internal reporting and forecasting purposes, when publicly providing its business outlook, to evaluate the company's performance and to evaluate and compensate the company's executives. The company has provided these non-GAAP financial measures in addition to GAAP financial results because it believes that these non-GAAP adjusted financial measures provide investors with a better understanding of the company's historical results from its core business operations.
While management believes that these non-GAAP adjusted financial measures provide useful supplemental information to investors regarding the underlying performance of the company's business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the company's results of operations as determined in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future.
Scripts Update for Week Ending 20/04
V
TRx: 25,144 {vs 25,236; -0.36%} Sector -0.33% -- 7th ATH
NRx: 10,192 {vs 10,236; -0.43%} Sector -0.41% -- 2nd ATH
Ref: 14,952 {vs 15,000; -0.32%} Sector -0.28%
GenL
TRx: 49,798 {vs 49,899; -0.20%}
NRx: 20,336 {vs 20,399; -0.31%}
L
TRx: 3,282 {vs 3,349; -2.00%}
NRx: 1,361 {vs 1,386; -1.80%}
V TRx Market Share: 32.14% vs 32.15% -- 2nd ATH
V NRx Market Share: 31.96% vs 31.97% -- 5th ATH
V Ref Market Share: 32.27% vs 32.28% -- 2nd ATH
Q1-2018 vs. Q1-2018 (Retail + Inst. Data)
V
TRx: 335,991 {vs 268,440; +25.16%} – Sector +2.76% --- 2nd ATH
NRx: 120,892 {vs 107,921; +12.02%} – Sector -0.36% --- 2nd ATH
Ref: 215,099 {vs 160,519; +34.00%} – Sector +4.53% --- 2nd ATH
Gen L
TRx: 716,768 {vs 778,660; -7.95%}
NRx: 246,640 {vs 272,515; -9.49%}
L
TRx: 48,377 {vs 24,453; +97.84%}
NRx: 18,832 {vs 7,325; +157.04%}
V Q1-2018 Retail+Inst. TRx Market Share: 30.51% vs 25.05% in Q1-2017 -- 2nd ATH
V Q1-2018 Retail+Inst. NRx Market Share: 31.29% vs 27.83% in Q1-2017 -- 2nd ATH
V Q1-2018 Retail+Inst. Ref Market Share: 30.09% vs 23.47% in Q1-2017 -- 2nd ATH
Mar-2018 vs. Mar-2017 (Retail + Inst. Data)
V
TRx: 117,933 {vs 98,977; +19.15%} -- Sector +0.74% --- 2nd ATH
NRx: 43,420 {vs 39,967; +8.64%} – Sector -1.69% -- ATH
Ref: 74,513 {vs 59,010; +26.27%} – Sector +2.13%
Gen L
TRx: 248,180 {vs 272,735; -9.00%}
NRx: 85,972 {vs 95,701; -10.17%}
L
TRx: 16,380 {vs 7,968; +105.57%}
NRx: 6,287 {vs 2,340; +168.68%}
V Mar-2018 Retail+Inst. TRx Market Share: 30.83% vs 26.07% in Mar-2017 – 3rd ATH
V Mar-2018 Retail+Inst. NRx Market Share: 32.00% vs 28.96% in Mar-2017 -- ATH
V Mar-2018 Retail+Inst. Ref Market Share: 30.19% vs 24.42% in Mar-2017 – 4th ATH
Total Monthly Retail + Institutional Data March-2018
V
TRx: 117,933 {vs 104,438; +12.92%} -- Sector +10.98% --- 2nd ATH
(Inst # 8,953 vs 8,733; +2.52% -- Inst Sec +0.17% -- Inst Mkt Sh 23.62% vs 23.08%)
NRx: 43,420 {vs 37,832; +14.77%} – Sector +12.74% -- ATH
Ref: 74,513 {vs 66,606; +11.87%} – Sector +10.04%
Gen L
TRx: 248,180 {vs 224,965; +10.32%}
(Inst # 27,360 vs 27,585; -0.82%)
NRx: 85,972 {vs 76,660; +12.15%}
L
TRx: 16,380 {vs 15,239; +7.49%}
(Inst # 1,590 vs 1,519; +4.67%)
NRx: 6,287 {vs 5,860; +7.29%}
V Monthly Retail + Inst. TRx Market Share: 30.83% vs 30.30% -- 3rd ATH
V Monthly Retail + Inst. NRx Market Share: 32.00% vs 31.43% -- ATH
V Monthly Retail + Inst. Ref Market Share: 30.19% vs 29.70% -- 4th ATH
Raf
Yup, as per below from their website
Welcome to the VITAL Study
Welcome to the Web site of the VITamin D and OmegA-3 TriaL (VITAL) at Brigham and Women’s Hospital, an affiliate of Harvard Medical School, in Boston, Massachusetts. VITAL is an ongoing research study in 25,874 men and women across the U.S. investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk for developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. Please click on Study Q&A to learn more about this important research endeavor.
Scripts Update for Week Ending 13/04
ATH in NRX Numbers & ATH in Market Share of TRx and Refills
V
TRx: 25,236 {vs 24,994; +0.97%} Sector -0.85% -- 5th ATH
NRx: 10,236 {vs 9,772; +4.75%} Sector +3.07% -- ATH
Ref: 15,000 {vs 15,222; -1.46%} Sector -3.39%
GenL
TRx: 49,899 {vs 51,048; -2.25%}
NRx: 20,399 {vs 19,936; +2.32%}
L
TRx: 3,349 {vs 3,116; +7.48%}
NRx: 1,386 {vs 1,359; +1.99%}
V TRx Market Share: 32.15% vs 31.57% -- ATH
V NRx Market Share: 31.97% vs 31.45% -- 4th ATH
V Ref Market Share: 32.28% vs 31.65% -- ATH
Q1-2018 vs. Q1-2017 (Retail ONLY Data)
V
TRx: 308,835 {vs 257,422; +19.97%} – Sector -0.17% ---3rd ATH
NRx: 120.892 {vs 107,921; +12.02%} – Sector -0.36% ---2nd ATH
Ref: 187,943 {vs 149,501; +25.71%} – Sector -0.05% ---3rd ATH
Gen L
TRx: 637,090 {vs 713,250; -10.68%}
NRx: 246,640 {vs 272,515; -9.49%}
L
TRx: 44,080 {vs 21,057; +109.34%}
NRx: 18,832 {vs 7,325; +157.09%}
V Q1-2018 Retail ONLY TRx Market Share: 31.20% vs 25.96% in Q1-2017 – 2nd ATH
V Q1-2018 Retail ONLY NRx Market Share: 31.29% vs 27.83% in Q1-2017 – 2nd ATH
V Q1-2018 Retail ONLY Refills Market Share: 31.13% vs 24.75% in Q1-2017 – 2nd ATH
Mar-2018 vs. Mar-2017 (Retail ONLY Data)
V
TRx: 108,980 {vs 94,720; +15.05%} – Sector -1.41% -- ATH
NRx: 43,420 {vs 39,967; +8.64%} – Sector -1.69% -- ATH
Ref: 65,560 {vs 54,753; +19.74%} – Sector -1.23% -- 4th ATH
Gen L
TRx: 220,820 {vs 247,920; -10.93%}
NRx: 85,972 {vs 95,701; -10.17%}
L
TRx: 14,790 {vs 6,877; +115.06%}
NRx: 6,287 {vs 2,340; +168.68%}
V Mar-2018 Retail ONLY TRx Market Share: 31.64% vs 27.10% in Mar-2017 --- = ATH
V Mar-2018 Retail ONLY NRx Market Share: 32.00% vs 28.96% in Mar-2017 --- ATH
V Mar-2018 Retail ONLY Ref Market Share: 31.38% vs 25.89% in Mar-2017 --- 2nd ATH
Total Monthly Retail ONLY Data March-2018
V
TRx: 108,980 {vs 95,705; +13.87%} – Sector +12.32% -- ATH
NRx: 43,420 {vs 37,832; +14.77%} – Sector +12.74% -- ATH
Ref: 65,560 {vs 57,873; +13.28%} – Sector +12.04% -- 4th ATH
Gen L
TRx: 220,820 {vs 197,380; +11.88%}
NRx: 85,972 {vs 76,660; +12.15%}
L
TRx: 14,790 {vs 13,720; +7.80%}
NRx: 6,287 {vs 5,860; +7.29%}
Monthly Retail TRx Market Share: 31.64% vs 31.19% --- = ATH
Monthly Retail NRx Market Share: 32.00% vs 31.43% --- ATH
Monthly Retail Refills Market Share: 31.38% vs 31.04% --- 2nd ATH
Scripts Update for Week Ending 06/04
V
TRx: 24,994 {vs 24,455; +2.20%} Sector +2.87%
NRx: 9,772 {vs 9,743; +0.30%} Sector +2.92%
Ref: 15,222 {vs 14,712; +3.47%} Sector +2.83%
GenL
TRx: 51,048 {vs 49,000; +4.18%}
NRx: 19,936 {vs 19,025; +4.79%}
L
TRx: 3,116 {vs 3,498; -10.92%}
NRx: 1,359 {vs 1,417; -4.09%}
V TRx Market Share: 31.57% vs 31.78%
V NRx Market Share: 31.45% vs 32.28%
V Ref Market Share: 31.65% vs 31.46%
CON,
Retail and Inst. Numbers for March-2018 are not out yet, so Q1 numbers can't be calculated.
Historically my numbers are less than stated by Amarin, no idea why? but it's ok with me as long as it's more than i state :)
Scripts Update for Week Ending 30/03
Short Week if i remember well
V
TRx: 24,455 {vs 24,383; +0.30%} Sector -0.19 %
NRx: 9,743 {vs 9,440; +3.21%} Sector +0.79%
Ref: 14,712 {vs 14,943; -1.55%} Sector -0.81%
GenL
TRx: 49,000 {vs 49,629; -1.27%}
NRx: 19,025 {vs 19,147; -0.64%}
L
TRx: 3,498 {vs 3,085; +13.39%}
NRx: 1,417 {vs 1,360; +4.19%}
V TRx Market Share: 31.78% vs 31.63% -- 2nd ATH
V NRx Market Share: 32.28% vs 31.52% -- = ATH
V Ref Market Share: 31.46% vs 31.69% -- 6th ATH
Scripts Update for Week Ending 16/03
V
TRx: 24,578 {vs 24,925; -1.39%} Sector -1.79 %
NRx: 9,956 {vs 9,929; +0.27%} Sector +0.16% -- 2nd ATH
Ref: 14,622 {vs 14,996; -2.49%} Sector -3.04%
GenL
TRx: 49,739 {vs 50,997; -2.47%}
NRx: 19,629 {vs 19,741; -0.57%}
L
TRx: 3,598 {vs 3,410; +5.51%}
NRx: 1,577 {vs 1,443; +9.29%}
V TRx Market Share: 31.54% vs 31.42% -- 4th ATH
V NRx Market Share: 31.95% vs 31.91% -- 3rd ATH
V Ref Market Share: 31.27% vs 31.10%
Scripts Update for Week Ending 09/03
V
TRx: 24,925 {vs 25,165; -0.95%} Sector -1.09 %
NRx: 9,929 {vs 10,118; -1.87%} Sector -1.62% -- 2nd ATH
Ref: 14,996 {vs 15,047; -0.34%} Sector -0.75%
GenL
TRx: 50,997 {vs 51,581; -1.13%}
NRx: 19,741 {vs 20,094; -1.76%}
L
TRx: 3,410 {vs 3,461; -1.47%}
NRx: 1,443 {vs 1,412; +2.20%}
V TRx Market Share: 31.42% vs 31.38%
V NRx Market Share: 31.91% vs 31.99%
V Ref Market Share: 31.10% vs 30.97%
Feb-2018 vs. Feb-2017 (Retail ONLY Data)
V
TRx: 95,705 {vs 80,016; +19.61%} – Sector +0.31%
NRx: 37,832 {vs 34,222; +10.55%} – Sector -0.73%
Ref: 57,873 {vs 45,794; +26.38%} – Sector +0.99%
Gen L
TRx: 197,380 {vs 219,470; -10.07%}
NRx: 76,660 {vs 84,749; -9.54%}
L
TRx: 13,720 {vs 6,386; +114.84%}
NRx: 5,860 {vs 2,268; +158.38%}
V Feb-2018 Retail ONLY TRx Market Share: 31.19% vs 26.16% in Feb-2017
V Feb-2018 Retail ONLY NRx Market Share: 31.43% vs 28.23% in Feb-2017
V Feb-2018 Retail ONLY Ref Market Share: 31.04% vs 24.80% in Feb-2017
Total Monthly Retail ONLY Data February-2018
V
TRx: 95,705 {vs 104,150; -8.11%} – Sector -9.39%
NRx: 37,832 {vs 39,640; -4.56%} – Sector -7.66%
Ref: 57,873 {vs 64,510; -10.35%} – Sector -10.47%
Gen L
TRx: 197,380 {vs 218,890; -9.83%}
NRx: 76,660 {vs 84,008; -8.75%}
L
TRx: 13,720 {vs 15,570; -11.88%}
NRx: 5,860 {vs 6,685; -12.34%}
Monthly Retail TRx Market Share: 31.19% vs 30.76% --- 3rd ATH
Monthly Retail NRx Market Share: 31.43% vs 30.41% --- 3rd ATH
Monthly Retail Refills Market Share: 31.04% vs 30.97% --- 3rd ATH
Scripts Update for Week Ending 02/03
V
TRx: 25,165 {vs 23,668; +6.32%} Sector +5.78 % -- 5th ATH
NRx: 10,118 {vs 9,262; +9.24%} Sector +7.45% -- ATH
Ref: 15,047 {vs 14,406; +4.45%} Sector +4.73%
GenL
TRx: 51,581 {vs 48,956; +5.36%}
NRx: 20,094 {vs 18,811; +6.82%}
L
TRx: 3,461 {vs 3,197; +8.26%}
NRx: 1,412 {vs 1,357; +4.05%}
V TRx Market Share: 31.38% vs 31.22% -- 7th ATH
V NRx Market Share: 31.99% vs 31.47% -- 2nd ATH
V Ref Market Share: 30.97% vs 31.05%
Scripts Update for Week Ending 23/02
V
TRx: 23,668 {vs 23,635; +0.14%} Sector -0.19%
NRx: 9,262 {vs 9,361; -1.06%} Sector -1.83%
Ref: 14,406 {vs 14,274; +0.92%} Sector +0.89%
GenL
TRx: 48,956 {vs 48,822; +0.27%}
NRx: 18,811 {vs 19,045; -1.23%}
L
TRx: 3,197 {vs 3,505; -8.79%}
NRx: 1,357 {vs 1,574; -13.79%}
V TRx Market Share: 31.22% vs 31.11%
V NRx Market Share: 31.47% vs 31.22%
V Ref Market Share: 31.05% vs 31.04%
AMARIN ANNOUNCES START OF FINAL CLINICAL SITE VISITS IN THE REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY
http://investor.amarincorp.com/releasedetail.cfm?ReleaseID=1059190
AMARIN ANNOUNCES START OF FINAL CLINICAL SITE VISITS IN THE REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY
Study Results Anticipated to be Released by End of Q3 2018
BEDMINSTER, N.J. and DUBLIN, Ireland, March 01, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that final study-related visits have commenced for patients enrolled in its REDUCE-IT cardiovascular outcomes study. An important step in completion of this potentially landmark study is to have patients return to their clinical sites for final study data collection. Commencing final patient visits on March 1, 2018 is consistent with the company's estimated schedule of having results of this first of its kind study announced before the end of the third quarter of this year.
"We are excited that the REDUCE-IT trial is nearing completion and appreciative for the participation of patients and clinical sites in this important clinical study," commented Dr. Steven Ketchum, Amarin senior vice president, president of R&D, and chief scientific officer. "The commencement of final patient visits is a positive step towards completing this six-year, 8,175 patient study."
Amarin is intentionally blinded to the results of the study and will remain blinded to such results until after the study is completed and the database is locked. Final patient visits will be followed by adjudication of newly reported cardiovascular events in the study, completing data entry for the greater than 33,000 patient years of study in REDUCE-IT, and typical database quality control measures, known as cleaning. This will be followed by the database lock and final efficacy and safety analyses, including analysis of the trial's primary endpoint of time to the first major adverse cardiovascular events (MACE) in the study, and the analyses of more than thirty pre-defined secondary and tertiary endpoints. Publication of the study design can be found at https://doi.org/10.1002/clc.22692.
Interesting
The below answer lots of questions asked on the board before and coincide well with JL's theory of lowering inflammation thus lowering events (ie it is not only about lowering triglyceride....etc
From the call transcripts:
"This study is not designed to evaluate how much of this potential lowering of MACE is derived from lowering of triglyceride levels versus improving atherosclerotic process versus any of the other potential health benefits delivered by Vascepa. It is the totality of these potential benefits which matters most and which is being evaluated in REDUCE-IT."
AMARIN SPONSORS MULTIPLE SCIENTIFIC PRESENTATIONS SCHEDULED FOR 2018 AMERICAN COLLEGE OF CARDIOLOGY ANNUAL SCIENTIFIC SESSION & EXPO
http://investor.amarincorp.com/releasedetail.cfm?ReleaseID=1058983
Presentations to Include Additional Real-World Data, Clinical and Cost Analyses of Patient Outcomes From Managed Care Databases
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, is supporting the presentation of four accepted scientific presentations at the American College of Cardiology's 67th Annual Scientific Session and Expo in Orlando, March 10-12, 2018. These presentations, and the underlying data and findings to be presented, were prepared in collaboration with leading health organizations and physicians.
"Amarin is pleased to be working in partnership with leading academic institutions and healthcare providers to research and identify these new and important findings," said Craig B. Granowitz, M.D., Ph.D., senior vice president and chief medical officer of Amarin. "Analyses of cost and disease progression of patients with high triglycerides and other health states are important as tens of millions of adults have cardiovascular disease."
Data to be presented includes:
Poster Presentations
1) Triglycerides ≥150 mg/dL Associated With Greater Risk of Cardiovascular Events, Costs and Resource Utilization in High-Risk Statin-Treated Patients With Controlled Low-Density Lipoprotein Cholesterol: A Real-World Analysis. Peter P. Toth, Craig Granowitz, Michael Hull, Djibril Liassou, Amy Anderson, Sephy Philip
2) Long-Term Renal Function Worsens in High Cardiovascular Risk Patients With High Triglycerides and Well-Controlled Low-Density Lipoprotein Cholesterol in a Real-World Analysis. Peter P. Toth, Craig Granowitz, Michael Hull, Djibril Liassou, Amy Anderson, Sephy Philip
3) Increased Medical Care Costs in Patients with Statin-Controlled Low-Density Lipoprotein Cholesterol and Residual Hypertriglyceridemia. Gregory A. Nichols, Sephy Philip, Craig Granowitz, Kristi Reynolds, Sergio Fazio, Kaiser Permanente Center for Health Research , Portland, OR, USA
4) Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) Reduces Potentially Atherogenic Lipid, Lipoprotein, Apolipoprotein, and Inflammatory Parameters in High-Risk, Statin-Treated Patients With Persistent Elevated Triglycerides and High-Sensitivity C-reactive Protein: A Post hoc Subanalysis of the ANCHOR Study. Michael Miller, Christie M. Ballantyne, Harold E. Bays, Craig Granowitz, Ralph T. Doyle, Jr, Rebecca A. Juliano, Sephy Philip